Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RO7126209 Clear all
Active, not recruiting Phase 3 Interventional

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 4:25 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Phoenix, Arizona • Imperial, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 4:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

NCT04023994
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 19, 2026, 4:25 PM EDT